Abbvie Inc. Common Stock (ABBV) 66.07 $ABBV
4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
The Half-Million Dollar Income Project
The Value Portfolio - at Seeking Alpha - Sun Apr 26, 2:40AM CDT
T: 34.01 (-0.22), NLY: 10.25 (-0.01), HCP: 42.45 (-0.12), ESV: 24.04 (-0.23), EDU: 26.52 (-0.17), ABBV: 66.07 (+1.82), TSM: 24.91 (+0.61), WMC: 14.91 (+0.07), RCS: 9.30 (+0.02), PGN: 1.69 (unch), CVX: 109.87 (-0.10), NE: 15.67 (-0.40)
I Called It: What's The Take Home Message?
Pharma Doc - at Seeking Alpha - Sun Apr 26, 12:52AM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
Preliminary data show 100% SVR4 for Viekirax + Exviera
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:48PM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), ENTA: 37.14 (+0.56)
AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX(R) + EXVIERA(R) in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress(TM) 2015
PR Newswire Europe - Sat Apr 25, 9:00AM CDT
- RUBY-I evaluates treatment-naive, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment
ABBV: 66.07 (+1.82), ENTA: 37.14 (+0.56)
AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress(TM) 2015
PR Newswire - Sat Apr 25, 9:00AM CDT
AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) with or without ribavirin (RBV) in treatment-naïve, non-cirrhotic, genotype 1 (GT1) chronic hepatitis C patients with severe renal impairment (stage 4 or 5), including those on hemodialysis. The primary endpoint of the study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR12). Patients who reached post-treatment week four to date (n=10 of 20 enrolled) achieved 100 percent SVR4 (n=10/10).1 RUBY-I was presented as a late-breaker today at The International Liver Congress(TM) (ILC) 2015, the 50th annual meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.
ABBV: 66.07 (+1.82), ENTA: 37.14 (+0.56)
Astra Deals Add To Ballooning Up-Front Payments
EP Vantage - at Seeking Alpha - Sat Apr 25, 7:10AM CDT
The brace of licensing deals unveiled by AstraZeneca (NYSE: AZN ) today are remarkable for their generous up-front payments - but not as remarkable as they might once have been. An analysis of the biggest up-front outlays of the past 10 years shows...
PFE: 35.27 (-0.09), AZN: 71.79 (-1.34), ABBV: 66.07 (+1.82)
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 5:28PM CDT
Merck reported encouraging data from an ongoing pivotal phase III program evaluating its grazoprevir/elbasvir.
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:36PM CDT
AbbVie's (ABBV) experimental HCV treatment is under priority review in the U.S. for the treatment of adults suffering from chronic genotype 4 HCV infection.
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AVEO: 1.92 (-0.08), ABBV: 66.07 (+1.82)
French biotech's B-vitamin beats placebo in Phase 3 MS study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:57AM CDT
BIIB: 401.71 (-28.57), OPXA: 0.43 (-0.01), FWP: 32.03 (-0.06), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
No Hiding From Respirageddon For Boehringer
EP Vantage - Seeking Alpha - Fri Apr 24, 11:49AM CDT
Given the hammering that US prices of respiratory drugs have taken as payers assaulted GlaxoSmithKline ’s (NYSE: GSK ) Advair it might come as a shock that sales of Boehringer Ingelheim ’s blockbuster Spiriva fell just...
ABBV: 66.07 (+1.82), GSK: 46.59 (+0.28)
Merck's HCV combo shows cure rates of 60 - 100% in three genotypes
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:05AM CDT
JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
AbbVie (ABBV) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Fri Apr 24, 2:32AM CDT
The following AbbVie (ABBV) conference call took place on April 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 66.07 (+1.82)
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C
PR Newswire Europe - Thu Apr 23, 11:45PM CDT
- The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent sustained virologic response rates at 12 weeks post-treatment with no discontinuations due to adverse events
ABBV: 66.07 (+1.82)
Biogen Earnings Preview: What To Look For
at Investor's Business Daily - Thu Apr 23, 6:45PM CDT
Biogen (BIIB) on Friday morning is expected to report earnings of $3.91 a share, up 58% vs. a year earlier. That would end a three-quarter string of accelerating growth. Sales should show a 25% advance to $2.66 billion, a solid gain but the fourth...
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:00PM CDT
Gilead Sciences, Inc. announced encouraging data from several phase II studies evaluating hepatitis C virus drugs.
BIIB: 401.71 (-28.57), JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), ABBV: 66.07 (+1.82)
AbbVie's (ABBV) CEO Rick Gonzalez on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 4:29PM CDT
ABBV: 66.07 (+1.82)
Pfizer's Once And Future Deals
Chris DeMuth Jr. - at Seeking Alpha - Thu Apr 23, 2:39PM CDT
SHAK: 68.53 (+5.80), GS: 197.99 (-1.32), MDT: 77.61 (-0.89), JPM: 62.60 (-0.20), SHPG: 255.11 (-0.26), COV: 106.71 (-1.36), PFE: 35.27 (-0.09), AZN: 71.79 (-1.34), BAC: 15.64 (-0.05), ABBV: 66.07 (+1.82), HSP: 87.61 (-0.05), MS: 37.36 (-0.02)
4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
The Half-Million Dollar Income Project
The Value Portfolio - at Seeking Alpha - Sun Apr 26, 2:40AM CDT
T: 34.01 (-0.22), NLY: 10.25 (-0.01), HCP: 42.45 (-0.12), ESV: 24.04 (-0.23), EDU: 26.52 (-0.17), ABBV: 66.07 (+1.82), TSM: 24.91 (+0.61), WMC: 14.91 (+0.07), RCS: 9.30 (+0.02), PGN: 1.69 (unch), CVX: 109.87 (-0.10), NE: 15.67 (-0.40)
I Called It: What's The Take Home Message?
Pharma Doc - at Seeking Alpha - Sun Apr 26, 12:52AM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
Preliminary data show 100% SVR4 for Viekirax + Exviera
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:48PM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), ENTA: 37.14 (+0.56)
AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX(R) + EXVIERA(R) in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress(TM) 2015
PR Newswire Europe - Sat Apr 25, 9:00AM CDT
- RUBY-I evaluates treatment-naive, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment
ABBV: 66.07 (+1.82), ENTA: 37.14 (+0.56)
AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress(TM) 2015
PR Newswire - Sat Apr 25, 9:00AM CDT
AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) with or without ribavirin (RBV) in treatment-naïve, non-cirrhotic, genotype 1 (GT1) chronic hepatitis C patients with severe renal impairment (stage 4 or 5), including those on hemodialysis. The primary endpoint of the study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR12). Patients who reached post-treatment week four to date (n=10 of 20 enrolled) achieved 100 percent SVR4 (n=10/10).1 RUBY-I was presented as a late-breaker today at The International Liver Congress(TM) (ILC) 2015, the 50th annual meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.
ABBV: 66.07 (+1.82), ENTA: 37.14 (+0.56)
Astra Deals Add To Ballooning Up-Front Payments
EP Vantage - at Seeking Alpha - Sat Apr 25, 7:10AM CDT
The brace of licensing deals unveiled by AstraZeneca (NYSE: AZN ) today are remarkable for their generous up-front payments - but not as remarkable as they might once have been. An analysis of the biggest up-front outlays of the past 10 years shows...
PFE: 35.27 (-0.09), AZN: 71.79 (-1.34), ABBV: 66.07 (+1.82)
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 5:28PM CDT
Merck reported encouraging data from an ongoing pivotal phase III program evaluating its grazoprevir/elbasvir.
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:36PM CDT
AbbVie's (ABBV) experimental HCV treatment is under priority review in the U.S. for the treatment of adults suffering from chronic genotype 4 HCV infection.
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AVEO: 1.92 (-0.08), ABBV: 66.07 (+1.82)
French biotech's B-vitamin beats placebo in Phase 3 MS study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:57AM CDT
BIIB: 401.71 (-28.57), OPXA: 0.43 (-0.01), FWP: 32.03 (-0.06), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
No Hiding From Respirageddon For Boehringer
EP Vantage - Seeking Alpha - Fri Apr 24, 11:49AM CDT
Given the hammering that US prices of respiratory drugs have taken as payers assaulted GlaxoSmithKline ’s (NYSE: GSK ) Advair it might come as a shock that sales of Boehringer Ingelheim ’s blockbuster Spiriva fell just...
ABBV: 66.07 (+1.82), GSK: 46.59 (+0.28)
Merck's HCV combo shows cure rates of 60 - 100% in three genotypes
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:05AM CDT
JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
AbbVie (ABBV) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Fri Apr 24, 2:32AM CDT
The following AbbVie (ABBV) conference call took place on April 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 66.07 (+1.82)
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C
PR Newswire Europe - Thu Apr 23, 11:45PM CDT
- The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent sustained virologic response rates at 12 weeks post-treatment with no discontinuations due to adverse events
ABBV: 66.07 (+1.82)
Biogen Earnings Preview: What To Look For
at Investor's Business Daily - Thu Apr 23, 6:45PM CDT
Biogen (BIIB) on Friday morning is expected to report earnings of $3.91 a share, up 58% vs. a year earlier. That would end a three-quarter string of accelerating growth. Sales should show a 25% advance to $2.66 billion, a solid gain but the fourth...
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:00PM CDT
Gilead Sciences, Inc. announced encouraging data from several phase II studies evaluating hepatitis C virus drugs.
BIIB: 401.71 (-28.57), JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), ABBV: 66.07 (+1.82)
AbbVie's (ABBV) CEO Rick Gonzalez on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 4:29PM CDT
ABBV: 66.07 (+1.82)
Pfizer's Once And Future Deals
Chris DeMuth Jr. - at Seeking Alpha - Thu Apr 23, 2:39PM CDT
SHAK: 68.53 (+5.80), GS: 197.99 (-1.32), MDT: 77.61 (-0.89), JPM: 62.60 (-0.20), SHPG: 255.11 (-0.26), COV: 106.71 (-1.36), PFE: 35.27 (-0.09), AZN: 71.79 (-1.34), BAC: 15.64 (-0.05), ABBV: 66.07 (+1.82), HSP: 87.61 (-0.05), MS: 37.36 (-0.02)
